Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant add-on long-term safety study in uncontrolled moderate-to-severe asthma
NL-OMON48545Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fevipiprant, sponsored by Novartis. Started Nov 2017; status: active, not recruiting.
02
Drugs
fevipiprant
Beyond the preview
Go deeper on NL-OMON48545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48545.